3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Dermatologic
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sarcoma, Kaposi
1
Melanoma
1
HIV Infections
1
Adenoviridae Infections
1
Acquired Immunodeficiency Syndrome
1
Interventions
pembrolizumab
92
Nivolumab
56
Ipilimumab
55
Cyclophosphamide
52
Vemurafenib
28
fludarabine
27
aldesleukin
25
Interleukin-2
25
fludarabine phosphate
21
trametinib
20
dabrafenib
17
Temozolomide
14
Biopsy
14
Cisplatin
13
spartalizumab
12
atezolizumab
12
Carboplatin
11
cobimetinib
10
Specimen Handling
10
Paclitaxel
10
Introns
10
CTLA-4 Antigen
10
poly ICLC
9
binimetinib
9
Radiotherapy
9
Radiosurgery
9
MART-1 Antigen
9
tremelimumab
8
incomplete Freund's adjuvant
8
Radiation
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Melanoma
×
Tumor Necrosis Factor-alpha
×
Clear all
NCT05222932
2025-08-07
AVENTIL
TILT Biotherapeutics Ltd.
Phase 1
Active not recruiting
15 enrolled